Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APTO 253

Next Previous
Search
Drug Profile

APTO 253

Alternative Names: APTO-253; LOR-253; LOR-253 HCl; LT-253

Latest Information Update: 18 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics; Imidazoles; Indoles; Phenanthrolines; Small molecules
  • Mechanism of Action Apoptosis stimulants; GKLF protein stimulants; Proto-oncogene protein c-myc inhibitors; Transcription factor MTF-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 22 Mar 2022 APTO 253 is available for licensing as of 22 Mar 2022. https://www.aptose.com/
  • 29 Dec 2021 Aptose Biosciences withdrews its phase II trial prior to enrolment in Non-small cell lung cancer
  • 20 Dec 2021 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top